Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Alexandria Real Estate Equities-backed exosome therapy developer Codiak Biosciences has filed to raise up to $100m having pulled back from an earlier offering last year.

Alexandria Venture Investments contributed to a $91.5m round for Korro, which is working on RNA therapies for liver, eye and central nervous system diseases.

Optum Ventures returned to help the patient engagement platform developer close a round that came just two months after its last funding.

Wu Capital has led a series A round for Korro Bio, whose RNA editing technology was developed at UChicago-affiliated Marine Biological Laboratory.

Debiopharm Innovation Fund and Crédit Mutuel Innovation co-led an $11.9m round for the digital pain management technology provider.

University of Utah's drug discovery technology producer has raised series D funding to increase its post-money valuation to some $1.2bn.

The drug discovery technology producer received $50m from strategic partner Bayer in the round, which valued it at about $1.2bn post-money.

Illumina's cancer diagnostics spinoff, which has raised more than $1.9bn in funding, has filed to float on the Nasdaq Global Select Market.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.